To further evaluate the translational potential of Z36-MP5, we compared the experimental therapeutic effects between Z36-MP5 and the EZH2 inhibitors (GSK126), which have been FDA approved for patients with epithelioid sarcoma52 and are in Phase I/II clinical trials for patients with metastatic melanoma. This evidence concerns the gene EZH2 and metastatic melanoma.